Shares of Organogenesis Holdings Inc. (ORGO) fell 5.12% in Friday's intraday trading, following the release of a new local coverage determination (LCD) by the Centers for Medicare & Medicaid Services (CMS) regarding skin substitute grafts and cellular tissue-based products for treating diabetic foot ulcers and venous leg ulcers.
While Organogenesis welcomed the evidence-based approach and the inclusion of its NuShield product in the covered list, investors appear concerned about the potential impact of the new policy on reimbursement levels and future revenue.
The company acknowledged that the LCD decision could affect coverage and reimbursement levels for its products, which has been a key risk factor in the past. As Organogenesis navigates this new policy landscape, investors will closely monitor its ability to maintain profitability and growth momentum.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.